Patently for patients

Yogendra Kumar Sapru, the man who spearheaded the legal battle against Novartis on Glivec's patentability, may not mind having his name altered in certain circumstances - or so he says. Recently, when addressing a press conference in New Delhi's Press Club of India, Sapru's initials on the name-card on the dais erroneously appeared as Y P Sapru. The founder-chairman of the Cancer Patients' Aid Association took this in good humour and was quick to say, "If it has to be P instead of K, then P must stand for patients and not patents."